On December 12, 2025, CDT Equity Inc. (CDT) disclosed the sale of its subsidiary Conduit Pharmaceuticals Limited (CPL). The 8-K filing disclosed a $7 million transaction with Corvus Capital Limited, according to the filing.

The Sale and Purchase Agreement, dated December 8, 2025, transfers CPL to Corvus Capital Limited for $7 million. As part of the settlement, CDT issued 3,910,615 shares of common stock and 3,685,815 pre-funded warrants to Corvus, according to the filing.

The pre-funded warrants are subject to shareholder approval and include a beneficial ownership limit of 49.99 percent of CDT's outstanding shares, as detailed in Exhibit 4.1. The filing notes that Nasdaq Stock Market LLC requires shareholder approval for the exercise of these warrants.

The filing also references concluded litigation between CPL and Strand Hanson Limited, which ended on October 28, 2025. The court ruling remains pending, according to the document.